Adjuvant chemotherapy in colon carcinoma stages II and III
- 42 Downloads
Adjuvant chemotherapy significantly improves disease-free survival and overall survival in colon cancer. Ongoing clinical trials are evaluating the addition of targeted therapies to standard regimen and the influence of gene expression signature as prognostic and predictive markers for the use of adjuvant chemotherapy. This review will summarize adjuvant therapeutic approaches in stages III and II colon cancer as well as therapeutic options in elderly patients and future developments in the adjuvant setting of colon cancer.
KeywordsColorectal cancer Adjuvant treatment Targeted therapy Elderly cancer patients
Unable to display preview. Download preview PDF.
- Mathers C, Boschi-Pinto C. Global burden of cancer in the year 2000: version 1 estimates. World Health Organization, Geneva, 2003Google Scholar
- O'Connell, Maggard MA, Ko CY, et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Nat Cancer Inst, 961420–961425, 2004Google Scholar
- Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol, 17: 3553–3559, 1999PubMedGoogle Scholar
- Haller D, Catalano P, Macdonald J, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancers: Five-year final report of INT-0089. Proc Am Soc Clin Oncol, 17: 982, 1998Google Scholar
- Köhne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluoruracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol, 21: 3721–3728, 2003PubMedCrossRefGoogle Scholar
- Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and Tegafur plus leucovorin compared with intravenous flourouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol, 24: 2059–2064, 2006PubMedCrossRefGoogle Scholar
- Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol, 23: 246 (Abstract 3500), 2004Google Scholar
- Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumors treated with FOLFOX4 + Cetuximab as 1st-line treatment for metastatic colorectal cancer: The Opus study. ECCO-ESMO, Abstract No 6.079, 2009Google Scholar
- Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol, 28: 4697–4705, 2010PubMedCrossRefGoogle Scholar
- De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results form a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX-4 versus FOLFOX-4 alone as adjuvant treatment for colon cancer. ASCO GI 2011, Abstract 362Google Scholar
- Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol, 27: 1814–1821, 2009PubMedCrossRefGoogle Scholar